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Background: It is unclear whether patients with few cerebral metastases benefit from whole-brain irradiation added
to radiosurgery. Since primary tumors disseminating to the brain show different behavior, this question should be
answered separately for each tumor type. This study compared both treatments in patients with 1-3 cerebral
metastases from lung cancer.
Methods: Ninety-eight patients receiving radiosurgery alone were retrospectively compared to 50 patients
receiving radiosurgery plus whole-brain irradiation for local control, distant cerebral control and overall survival.
Ten other characteristics were additionally considered including radiosurgery dose, age, gender, Eastern Cooperative
Oncology Group (ECOG) performance score, histology, number of cerebral metastases, maximum diameter of all
cerebral metastases, site of cerebral metastases, extra-cerebral metastases, and interval from lung cancer diagnosis
to irradiation.
Results: The treatment approach had no significant impact on local control (p = 0.61). On multivariate analysis
of local control, ECOG performance score was significant (risk ratio [RR]: 2.10; p < 0.001). The multivariate analysis
of distant brain control revealed significant positive associations with radiosurgery plus whole-brain irradiation
(RR: 4.67; p < 0.001) and one cerebral metastasis (RR: 2.62; p < 0.001). Treatment approach was not significantly
associated with overall survival (p = 0.32). On multivariate analysis, significant associations with overall survival were
found for maximum diameter of all cerebral metastases (RR: 1.81; p = 0.008), extra-cerebral metastases (RR: 2.98;
p < 0.001), and interval from lung cancer diagnosis to irradiation (RR: 1.19; p < 0.001).
Conclusion: Addition of whole-brain irradiation to radiosurgery significantly improved distant brain control in patients
with few cerebral metastases from lung cancer. This improvement did not translate into better overall survival.
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About 50% of all patients presenting with cerebral me-
tastasis from a solid tumor have lung cancer [1]. There-
fore, this group of patients requires particular attention.
Patients presenting with multiple metastases are generally
treated with whole-brain irradiation alone [2]. In contrast,
many patients with very few cerebral metastases are con-
sidered candidates for local therapies such as neuro-
surgery and radiosurgery [3,4]. Whereas neurosurgical* Correspondence: rades.dirk@gmx.net
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lesion, radiosurgery is also administered for more than
one metastasis. If radiosurgery is given, it is still not clear
whether it should be supplemented by whole-brain irradi-
ation. Those physicians who hesitate in adding whole-
brain irradiation are concerned about the potential for
increased risk of neuro-cognitive deficits, which has
been shown in a small randomized trial [5]. They argue
that in case of new cerebral metastases, additional ra-
diosurgery could be applied. Furthermore, randomized
trials revealed that the addition of whole-brain irradiation
did not lead to improved overall survival [6,7]. The pro-
tagonists of additional whole-brain radiotherapy arguetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,









<20 Gy (n = 63) 38 (39) 25 (50)
≥20 Gy (n = 85) 60 (61) 25 (50) 0.46
Age
≤59 years (n = 76) 49 (50) 27 (54)
≥60 years (n = 72) 49 (50) 23 (46) 0.86
Gender
Female (n = 68) 47 (48) 21 (42)
Male (n = 80) 51 (52) 29 (58) 0.73
ECOG Performance Score
0-1 (n = 93) 64 (65) 29 (58)
2 (n = 55) 34 (35) 21 (42) 0.68
Histology
Adenocarcinoma (n = 92) 62 (63) 30 (60)
Others (n = 56) 36 (37) 20 (40) 0.89
Number of cerebral
metastases
1 (n = 90) 61 (62) 29 (58)
2-3 (n = 58) 37 (38) 21 (42) 0.84
Maximum diameter of
all cerebral metastases
≤18 mm (n = 75) 50 (51) 25 (50)
≥19 mm (n = 73) 48 (49) 25 (50) 0.97
Main site of cerebral
metastases
Supratentorial (n = 127) 84 (86) 43 (86)
Infratentorial (n = 21) 14 (14) 7 (14) 0.99
Extra-cerebral metastases
No (n = 95) 64 (65) 31 (62)
Yes (n = 53) 34 (35) 19 (38) 0.89
Interval from lung cancer
diagnosis to irradiation
≤11 months (n = 77) 51 (52) 26 (52)
≥12 months (n = 71) 47 (48) 24 (48) 0.99
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distant cerebral control and overall brain control [8,9]. In-
tracerebral recurrence is an important cause of neuro-
cognitive decline and should, therefore, be avoided as long
as possible. These randomized trials included patients
with cerebral metastases from a great variety of primary
tumors [5-9]. However, each primary tumor such as
lung cancer is characterized by specific biological and
clinical aspects and prognostic factors [10-12]. There-
fore, it appears helpful to take a specific look at each
primary tumor disseminating to the brain. An import-
ant question is, “whether it will be possible to identify
primary tumors that require the addition of whole-brain
irradiation to radiosurgery in order to improve the pa-
tients’ prognoses in terms of tumor control within the
brain and overall survival?” The present study aims to
contribute to this more detailed approach by comparing
radiosurgery alone to radiosurgery plus whole-brain ir-




Of a cohort of 148 patients who received radiosurgery
for 1-3 newly diagnosed brain metastases from lung can-
cer, 98 patients treated with radiosurgery alone were re-
trospectively compared to those 50 patients treated with
radiosurgery plus whole-brain irradiation. Investigated
endpoints were local control of the treated cerebral metas-
tases, distant cerebral control (freedom from new cerebral
metastases) and overall survival. Ninety-three of 98 pa-
tients (95%) and 47 of 50 patients (94%), respectively, re-
ceived linear accelerator-based radiosurgery, and the
remaining patients received CyberKnife treatment. The
selection of the treatment approach for an individual pa-
tient was based on the treating physicians’ opinions.
In addition to the treatment approach, ten other cha-
racteristics were considered such as radiosurgery dose
(<20 Gy vs. ≥20 Gy, prescribed to the margin of the meta-
static lesions representing the 75-90% isodose level), age
at the start of radiotherapy (≤59 vs. ≥60 years, median:
59 years), gender, Eastern Cooperative Oncology Group
(ECOG) performance score (0-1 vs. 2), histology of the
primary tumor (adenocarcinoma vs. other histologies),
number of cerebral metastases (1 vs. 2-3), maximum
diameter of all cerebral metastases (≤18 mm vs. ≥19 mm,
median: 18 mm), main site of cerebral metastases (supra-
tentorial vs. infratentorial), extra-cerebral metastases (no
vs. yes) and the interval from lung cancer diagnosis to ir-
radiation (<12 vs. ≥12 months). The distribution of these
ten characteristics was not significantly different in both
treatment groups (Table 1). This retrospective study has
been approved by the local ethics committee (University
of Lübeck).Statistical considerations
The comparison of both treatment groups for the distri-
bution of the ten additionally investigated characteristics
was performed with the Chi-square test. The Kaplan-
Meier method and the log-rank test were used for the
univariate analyses of local control of the treated cerebral
metastases, distant cerebral control and overall survival.
Those characteristics that were significant or showed a
trend in the univariate analysis (p ≤ 0.060) were addi-
tionally analyzed in a multivariate manner with the Cox








Radiosurgery alone (n = 98) 90 80
Radiosurgery +WBI (n = 50) 98 86 0.61
Radiosurgery dose
<20 Gy (n = 63) 88 76
≥20 Gy (n = 85) 97 87 0.39
Age
≤59 years (n = 76) 93 89
≥60 years (n = 72) 93 73 0.50
Gender
Female (n = 68) 95 84
Male (n = 80) 90 80 0.70
ECOG Performance Score
0-1 (n = 93) 96 88
2 (n = 55) 86 70 <0.001
Histology
Adenocarcinoma (n = 92) 95 86
Others (n = 56) 89 76 0.16
Number of cerebral metastases
1 (n = 90) 93 81
2-3 (n = 58) 92 84 0.39
Maximum diameter of all cerebral
metastases
≤18 mm (n = 75) 91 87
≥19 mm (n = 73) 95 74 0.051
Main site of cerebral metastases
Supratentorial (n = 127) 93 81
Infratentorial (n = 21) 88 88 0.20
Extra-cerebral metastases
No (n = 95) 94 84
Yes (n = 53) 90 79 0.10
Interval from lung cancer diagnosis
to irradiation
≤11 months (n = 77) 97 83
≥12 months (n = 71) 89 80 0.46
Significant p-values are given in bold.
Figure 1 Comparison of the two treatment groups for distant
brain control.
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death or for a median of 12 months (range: 6-39 months)
in survivors.
Results
Better local control of the treated metastases was signi-
ficantly associated with an ECOG performance score of
0-1 (p < 0.001) and almost significantly associated with amaximum diameter of all cerebral metastases of ≤18 mm
(p = 0.051) on univariate analyses. The treatment approach
had no significant impact on local control (p = 0.61). A
summary of the results of the univariate analysis of local
control is given in Table 2. On multivariate analysis of
local control, the ECOG performance score was signi-
ficant (risk ratio [RR]: 2.10; 95%-confidence interval [CI]:
1.38-3.29; p < 0.001), whereas the maximum diameter
of all cerebral metastases was not significant (RR: 1.19;
95%-CI: 0.52-2.81; p = 0.68).
Distant intra-cerebral control was positively associated
with radiosurgery plus whole-brain irradiation (p < 0.001,
Figure 1) and with presence of only one cerebral lesion
(p = 0.002) in the univariate analyses (Table 3). In the sub-
sequent multivariate analysis, both treatment approach
(RR: 4.67; 95%-CI: 2.23-11.36; p < 0.001) and the num-
ber of cerebral metastases (RR: 2.62; 95%-CI: 1.49-4.68;
p < 0.001) remained significant.
In the univariate analysis of the third evaluated end-
point, overall survival, significant positive associations
were observed for an ECOG performance score of 0-1
(p < 0.001), a maximum diameter of all cerebral metasta-
ses ≤18 mm (p = 0.003), and lack of extra-cerebral me-
tastases (p < 0.001). A trend towards improved overall
survival was observed for an interval from lung cancer
diagnosis to irradiation of <12 months (p = 0.060). The
treatment approach was not significantly associated with
overall survival (p = 0.32). The results of the entire uni-
variate analysis are shown in Table 4. In the corresponding
multivariate analysis, maximum diameter of all cere-
bral metastases (RR: 1.81; 95%-CI: 1.1-2.83; p = 0.008),
extra-cerebral metastases (RR: 2.98; 95%-CI: 1.92-4.64;
p < 0.001), and interval from lung cancer diagnosis to ir-
radiation (RR: 1.19; 95%-CI: 1.14-1.25; p < 0.001) were sig-
nificant, whereas the ECOG performance score was not
(RR: 1.19; 95%-CI: 0.95-1.49; p = 0.13).







Radiosurgery alone (n = 98) 68 48
Radiosurgery +WBI (n = 50) 96 83 <0.001
Radiosurgery dose
<20 Gy (n = 63) 72 63
≥20 Gy (n = 85) 82 59 0.92
Age
≤59 years (n = 76) 79 61
≥60 years (n = 72) 75 61 0.88
Gender
Female (n = 68) 80 57
Male (n = 80) 75 64 0.52
ECOG Performance Score
0-1 (n = 93) 77 61
2 (n = 55) 79 61 0.84
Histology
Adenocarcinoma (n = 92) 76 56
Others (n = 56) 81 71 0.17
Number of cerebral metastases
1 (n = 90) 81 72
2-3 (n = 58) 73 44 0.002
Maximum diameter of all cerebral
metastases
≤18 mm (n = 75) 82 63
≥19 mm (n = 73) 72 59 0.16
Main site of cerebral metastases
Supratentorial (n = 127) 77 59
Infratentorial (n = 21) 82 72 0.39
Extra-cerebral metastases
No (n = 95) 81 63
Yes (n = 53) 73 57 0.36
Interval from lung cancer diagnosis
to irradiation
≤11 months (n = 77) 83 58
≥12 months (n = 71) 73 62 0.75
Significant p-values are given in bold.







Radiosurgery alone (n = 98) 68 49
Radiosurgery +WBI (n = 50) 78 59 0.32
Radiosurgery dose
<20 Gy (n = 63) 75 51
≥20 Gy (n = 85) 69 54 0.45
Age
≤59 years (n = 76) 74 63
≥60 years (n = 72) 69 41 0.10
Gender
Female (n = 68) 82 61
Male (n = 80) 63 46 0.16
ECOG Performance Score
0-1 (n = 93) 76 61
2 (n = 55) 64 38 <0.001
Histology
Adenocarcinoma (n = 92) 76 64
Others (n = 56) 64 33 0.10
Number of cerebral metastases
1 (n = 90) 74 54
2-3 (n = 58) 67 50 0.51
Maximum diameter of all cerebral
metastases
≤18 mm (n = 75) 77 62
≥19 mm (n = 73) 66 42 0.003
Main site of cerebral metastases
Supratentorial (n = 127) 72 53
Infratentorial (n = 21) 67 51 0.72
Extra-cerebral metastases
No (n = 95) 86 67
Yes (n = 53) 45 28 <0.001
Interval from lung cancer diagnosis
to irradiation
≤11 months (n = 77) 64 47
≥12 months (n = 71) 80 59 0.060
Significant p-values are given in bold.
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For patients with very few cerebral metastases, the benefit
of the addition of whole-brain irradiation to radiosurgery
is still uncertain. The major concern, which prevents a
considerable proportion of radiation oncologists from de-
livering additional whole-brain irradiation, is the fear of
treatment-related decline in neuro-cognitive function.
For example, a randomized trial was stopped early, be-
cause the rate of neuro-cognitive deficits was significantlygreater after radiosurgery plus whole-brain irradiation
than after radiosurgery alone at four months following
irradiation [5]. However, at one year following treat-
ment, intra-cerebral control was significantly better in
the group of patients who had received the combined
approach. Unfortunately, the authors did not evaluate the
patients’ neuro-cognitive function at one year. This would
have been very important because several authors have
suggested that an intra-cerebral recurrence of metastatic
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reason of neuro-cognitive deficits in patients irradiated for
cerebral metastasis [8,9]. Therefore, it is very important to
prevent such an intra-cerebral recurrence. In the study
of Aoyama et al. neuro-cognitive function was better in
patients treated with radiosurgery plus whole-brain ir-
radiation when compared to patients treated with radio-
surgery alone at one year and two years after treatment
[8]. An argument often used against additional whole-
brain irradiation is the option of salvage radiosurgery in
case of an intra-cerebral recurrence distant from the
treated lesions. However, salvage radiosurgery is not al-
ways reasonable depending on the number of new cere-
bral metastases [13]. Therefore, it would be important
to have a tool to predict the probability of developing
new cerebral metastases. Such a tool has recently been
developed [14].
These considerations demonstrate the need for further
studies to address the potential benefit of whole-brain-
irradiation administered in addition to radiosurgery. As
the different primary tumors that lead to cerebral metas-
tases vary considerably with respect to biological and
clinical aspects and to prognostic factors, separate ana-
lyses of the different tumor types would likely facilitate
the identification of patients who may benefit from addi-
tional whole-brain irradiation [10-12].
The present study focused on patients with cerebral
metastasis from lung cancer, the most common primary
tumor among patients with metastases to the brain [1].
According to the results of this study, the addition of
whole-brain irradiation resulted in significantly improved
distant brain control at six and twelve months following
treatment. Given the results of the study of Aoyama et al.
improved brain control would likely result in less neuro-
cognitive decline [8]. Unfortunately, since the present
study had a retrospective design, valid data regarding
the patients’ neuro-cognitive function before and after
irradiation were not available. This important aspect
needs to be investigated in a future prospective trial in-
cluding only patients with cerebral metastases from
lung cancer. Furthermore, the retrospective design of our
study should to be taken into account when interpreting
the results. Retrospective studies always bear the risk of a
hidden selection bias.
In the present study, improvement of distant brain
control achieved with the addition of whole-brain irradi-
ation did not translate into improved overall survival.
This finding agrees with the results of the available ran-
domized trials of patients with cerebral metastasis from
many different primary tumors [6,7].
These results may lead to the question, whether the
addition of whole-brain irradiation is justified if it does
not improve overall survival? We feel that it should be
offered to most patients with cerebral metastasis fromlung cancer, as it can improve distant brain control which
likely translates to fewer neuro-cognitive deficits in the
long run [8]. One has to be aware that more than half
of the patients of the present study developed distant
cerebral metastases within one year if treated with ra-
diosurgery alone. Given a more conservative approach,
whole-brain irradiation should be offered at least to
those patients with a high risk of developing new brain
metastases. According to a recent study of patients with
cerebral metastases from different primary tumors, those
patients with both more than one cerebral lesion and
extra-cerebral metastases had the highest risk of de-
veloping new cerebral lesions [14]. At least these pa-
tients should receive whole-brain irradiation in addition
to radiosurgery.
Conclusions
The addition of whole-brain irradiation to radiosurgery
significantly improved distant brain control of patients
with very few cerebral metastases from lung cancer. Im-
provement of distant brain control did not translate into
better overall survival in these patients. Further studies
with more patients and a longer follow up are required
to better define the role of the addition of whole-brain
irradiation to radiosurgery in lung cancer patients with
very few cerebral metastases.
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